Trial Profile
A Study to Assess the Effect of Single Doses of MK -5475 on Pulmonary Vascular Resistance in Patients With Moderate to Severe Pulmonary Arterial Hypertension
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Dec 2022
Price :
$35
*
At a glance
- Drugs MK 5475 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
- 29 Nov 2022 Results published in the Respiratory Medicine
- 03 Jan 2021 Status changed from active, no longer recruiting to completed.
- 02 Nov 2020 Planned End Date changed from 5 Feb 2021 to 31 Dec 2020.